QC
GANX icon

Quadrature Capital’s Gain Therapeutics GANX Stock Holding History

Quadrature Capital’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,154
Closed -$38.3K – 1197
2025
Q1 		$38.3K Buy
+20,154
New +$44.7K ﹤0.01% 991

Other funds holding GANX

GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Quadrature Capital's GANX Position: Q2 2025 in Review

Quadrature Capital sold out of Gain Therapeutics (GANX) in Q2 2025, closing a stake of 20,154 shares — an estimated $38.3K sold.

Quadrature Capital first reported a position in GANX in Q1 2025 and held it in 1 quarter. The position peaked at $38.3K in Q1 2025. 35 funds tracked by Wall St. Rank hold GANX as of Q2 2025.

  • Quadrature Capital reported no remaining Gain Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Quadrature Capital sold 20,154 Gain Therapeutics shares in Q2 2025, an estimated $38.3K.
  • Quadrature Capital first reported a position in Gain Therapeutics in Q1 2025 and held it in 1 quarter.
  • Quadrature Capital's Gain Therapeutics position peaked at $38.3K in Q1 2025.
  • 35 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2025.

Based on Quadrature Capital's 13F filing for Q2 2025, filed 13 Aug 2025.